{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:41:11Z","timestamp":1785156071585,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970111"],"award-info":[{"award-number":["81970111"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Eltrombopag (ELT) is effective and safe in adult persistent\/chronic immune thrombocytopenia (p\/cITP); a proportion could achieve a sustained response off treatment (SRoT); however, data on children are lacking. We attempted to analyse SRoT of ELT in children with p\/cITP in this study. A multicentre retrospective observational study was performed in November 2022 for children with p\/cITP who used ELT alone for &gt;2\u2009months between January 2017 and November 2021. Clinical data of pre\u2010, during and post\u2010ELT were collected. SRoT was defined as maintaining a platelet count of \u226530\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L without rescue therapy for at least 6\u2009months off ELT. There were 143 patients enrolled; 69.2% (99\/143) achieved an overall response of 43.3% and 25.9% achieved complete response (CR) and response (R). Among the 35 patients analysed from whom ELT was withdrawn, 71.4% (25\/35) showed SRoT after discontinuing ELT without additional ITP therapy, with a median follow\u2010up of 0.94 (range, 0.53\u20133.8) years, equal to 17.5% (25\/143) in all patients treated with ELT. Compared with the patients with relapse (<jats:italic>n<\/jats:italic>\u2009=\u200910), the SRoT patients (<jats:italic>n<\/jats:italic>\u2009=\u200925) had a higher rate of CR (80% [20\/25] vs. 40% [4\/10]), shorter interval time from initiation to taper (6.4\u2009months vs. 9.4\u2009months), longer time from taper to withdrawal (1.1\u2009years vs. 0.3\u2009years) and a longer duration of ELT treatment (1.6\u2009years vs. 0.5\u2009years) with <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05. Patients who achieved CR could attain SRoT more easily (<jats:italic>p<\/jats:italic>\u2009=\u20090.02). ELT had a response in 69.2% of children with p\/cITP and 17.5% of them attained SRoT with good tolerance. The patients who achieved CR and began ELT treatment as early as possible, with a longer treatment duration and slower tapering, had a higher probability of SRoT.<\/jats:p>","DOI":"10.1111\/bjh.18842","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T08:00:36Z","timestamp":1683014436000},"page":"422-428","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Sustained response off treatment in eltrombopag for children with persistent\/chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China"],"prefix":"10.1111","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7363-5101","authenticated-orcid":false,"given":"Zhifa","family":"Wang","sequence":"first","affiliation":[{"name":"Hematology Center, Beijing Children's Hospital Capital Medical University, National Center for Children's Health  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology Henan Province Children's Hospital  Zhengzhou Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology Baoding Children's Hospital  Baoding Hebei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxi","family":"Meng","sequence":"additional","affiliation":[{"name":"Hematology Center, Beijing Children's Hospital Capital Medical University, National Center for Children's Health  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyue","family":"Dong","sequence":"additional","affiliation":[{"name":"Hematology Center, Beijing Children's Hospital Capital Medical University, National Center for Children's Health  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyao","family":"Ma","sequence":"additional","affiliation":[{"name":"Hematology Center, Beijing Children's Hospital Capital Medical University, National Center for Children's Health  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[{"name":"Hematology Center, Beijing Children's Hospital Capital Medical University, National Center for Children's Health  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology Research Beijing Children's Hospital, Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0048-2658","authenticated-orcid":false,"given":"Xiaoling","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Beijing Children's Hospital, Capital Medical University  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4030-209X","authenticated-orcid":false,"given":"Runhui","family":"Wu","sequence":"additional","affiliation":[{"name":"Hematology Center, Beijing Children's Hospital Capital Medical University, National Center for Children's Health  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-129155"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-466375"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200507050-00004"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225565"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2020.102505"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ped4.12313"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2019.09.001"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15732"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004110"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12888"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151886"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00114-3"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04804-z"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ped4.12305"},{"key":"e_1_2_11_17_1","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Available from:https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 27 November 2017."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.23.11104"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.212845"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1793-1"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23900"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2013.870987"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12139"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12169"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1159\/000510676"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17334"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010735"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.18842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T01:05:52Z","timestamp":1700010352000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.18842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1111\/bjh.18842"],"URL":"https:\/\/doi.org\/10.1111\/bjh.18842","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]},"assertion":[{"value":"2023-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}